Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Real-world and clinical trial outcomes in large B-cell lymphoma with axicabtagene ciloleucel across race and ethnicity
Jacobson, Caron A. , Ghobadi, Armin , Ahmed, Sairah , Miklos, David B. , Perales, Miguel‐Angel , Fingrut, Warren , Pennisi, Martina , Gowda, Lohith , Abid, Muhammad Bilal , Hong, Sanghee , Kharfan‐Dabaja, Mohamed A. , Khurana, Arushi , Badar, Talha , Hu, Zhen‐Huan , Wang, Hailin , Baer, Anjani, Baro, Elande , Miao, Harry , Spooner, Clare, Xu, Hairong, Pasquini, Marcelo C. , Ghobadi, Armin , Ahmed, Sairah , Miklos, David B , Perales, Miguel-Angel , Fingrut, Warren B , Shadman, Mazyar , Majhail, Navneet S , Kharfan-Dabaja, Mohamed A , Badar, Talha , Bennani, N Nora , Herr, Megan M. , Pasquini, Marcelo , Abid, Muhammad Bilal , Locke, Frederick L. , Siddiqi, Tanya , Muñoz, Javier , Gauthier, Jordan , Shadman, Mazyar , Mirza, Abu‐Sayeef , Majhail, Navneet S. , Lin, Yi , Bennani, N. Nora

Mayo Clinic

Blood | April 18, 2024 | Volume: 143 | Issue: 26 | Pages: 2722-2734

10.1182/blood.2023023447 | PMID 38635762 Get It

Abstract Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Despite extensive data supporting its use, outcomes stratified by race and ethnicity groups are limited. Here, we report clinical outcomes with axi-cel in patients with R/R LBCL by race and ethnicity in both real-world and clinical trial settings. In the real-world setting, 1290 patients who received axi-cel between 2017 and 2020 were identified from the Center for International Blood and Marrow Transplant Research database; 106 and 169 patients were included from the ZUMA-1 and ZUMA-7 trials, respectively. Overall survival was consistent across race/ethnicity groups. However, non-Hispanic (NH) Black patients had lower overall response rate (OR, 0.37; 95% CI, 0.22-0.63) and lower complete response rate (OR, 0.57; 95% CI, 0.33-0.97) than NH White patients. NH Black patients also had a shorter progression-free survival vs NH White (HR, 1.41; 95% CI, 1.04-1.90) and NH Asian patients (HR, 1.67; 95% CI, 1.08-2.59). NH Asian patients had a longer duration of response than NH White (HR, 0.56; 95% CI, 0.33-0.94) and Hispanic patients (HR, 0.54; 95% CI, 0.30-0.97). There was no difference in cytokine release syndrome by race/ethnicity; however, higher rates of any-grade immune effector cell–associated neurotoxicity syndrome were observed in NH White patients than in other patients. These results provide important context when treating patients with R/R LBCL with CAR T-cell therapy across different racial and ethnic groups. ZUMA-1 and ZUMA-7 (ClinicalTrials.gov identifiers: #NCT02348216 and #NCT03391466, respectively) are registered on ClinicalTrials.gov.
Managing the Lactating Patient Receiving Anesthesia: An Innovative Educational Initiative
Lehmann, Taylor, Morgan, Emily , Sharpe, Emily E. , Steege, Jenna, Schroeder, Darrell R. , Dodd, Sarah E. , Sharpe, Emily E , Dodd, Sarah, Schroeder, Darrell , Morgan, Emily, Steege, Jenna R.

Mayo Clinic

Journal of Women's Health | April 18, 2024 | Volume: 33 | Issue: 10 | Pages: 1344-1348

10.1089/jwh.2023.0875 | PMID 38634542 Get It

Background: Breastfeeding has numerous health benefits for patients and their infants. There are inconsistencies in how anesthesia providers care for lactating patients undergoing anesthesia. Providers may be cautious and have patients “pump and dump” instead of following current evidence-based recommendations. Video-based education provides a novel reference for health care providers in their fast-paced work environments. This project evaluated the effectiveness of an online video module and resources accessed at the bedside for anesthesia providers caring for lactating patients. Materials and Methods: A preintervention survey was sent to anesthesia providers at a large academic institution to assess baseline knowledge of current recommendations for caring for lactating patients having anesthesia. A quick response code-linked video module and references were created and disseminated to all anesthesia providers. A postsurvey was sent to assess knowledge and satisfaction with the educational approach. Postsurvey data were compared with presurvey data. Results: All who watched the educational video found the education helpful to care for lactating patients undergoing surgery. In the posteducation group, 93% of providers selected the correct recommendation to continue breastfeeding or pumping after general anesthesia or sedation once the patient is awake and alert, compared with 48% in the pre-education group. After education, 92% would recommend preoperative feeding or pumping prior to transport to the operating room, compared with the 50% in the pre-education group. Conclusions: Video-based, just-in-time education is an effective way to deliver updated information to anesthesia providers. This format is conducive to just-in-time delivery, and there may be implications for other patient populations that present infrequently but require population-specific care.
Cervical spondylotic myelopathy and driving abilities: defining the prevalence and long-term postoperative outcomes using the Quality Outcomes Database
Agarwal, Nitin , Johnson, Sarah E. , Bydon, Mohamad , Bisson, Erica F. , Chan, Andrew K. , Shabani, Saman , Michalopoulos, Giorgos D. , Lu, Daniel C. , Wang, Michael Y. , Haid, Regis W., Knightly, John J. , Sherrod, Brandon A. , Gottfried, Oren N., Shaffrey, Christopher I. , Virk, Michael S. , Hussain, Ibrahim , Glassman, Steven D. , Shaffrey, Mark E., Foley, Kevin T. , Pennicooke, Brenton , Coric, Domagoj , Slotkin, Jonathan R., Upadhyaya, Cheerag D., Potts, Eric A. , Tumialán, Luis M. , Chou, Dean , Fu, Kai-Ming, Asher, Anthony L. , Mummaneni, Praveen V. , Michalopoulos, Giorgos , Letchuman, Vijay , Lavadi, Raj Swaroop , Goldberg, Jacob L. , Park, Paul

Mayo Clinic

Journal of Neurosurgery: Spine | April 16, 2024 | Volume: 40 | Issue: 5 | Pages: 630-641

10.3171/2023.11.spine23738 | PMID 38364219 Get It

OBJECTIVE Cervical spondylotic myelopathy (CSM) can cause significant difficulty with driving and a subsequent reduction in an individual’s quality of life due to neurological deterioration. The positive impact of surgery on postoperative patient-reported driving capabilities has been seldom explored. METHODS The CSM module of the Quality Outcomes Database was utilized. Patient-reported driving ability was assessed via the driving section of the Neck Disability Index (NDI) questionnaire. This is an ordinal scale in which 0 represents the absence of symptoms while driving and 5 represents a complete inability to drive due to symptoms. Patients were considered to have an impairment in their driving ability if they reported an NDI driving score of 3 or higher (signifying impairment in driving duration due to symptoms). Multivariable logistic regression models were fitted to evaluate mediators of baseline impairment and improvement at 24 months after surgery, which was defined as an NDI driving score < 3. RESULTS A total of 1128 patients who underwent surgical intervention for CSM were included, of whom 354 (31.4%) had baseline driving impairment due to CSM. Moderate (OR 2.3) and severe (OR 6.3) neck pain, severe arm pain (OR 1.6), mild-moderate (OR 2.1) and severe (OR 2.5) impairment in hand/arm dexterity, severe impairment in leg use/walking (OR 1.9), and severe impairment of urinary function (OR 1.8) were associated with impaired driving ability at baseline. Of the 291 patients with baseline impairment and available 24-month follow-up data, 209 (71.8%) reported postoperative improvement in their driving ability. This improvement seemed to be mediated particularly through the achievement of the minimal clinically important difference (MCID) in neck pain and improvement in leg function/walking. Patients with improved driving at 24 months noted higher postoperative satisfaction (88.5% vs 62.2%, p < 0.01) and were more likely to achieve a clinically significant improvement in their quality of life (50.7% vs 37.8%, p < 0.01). CONCLUSIONS Nearly one-third of patients with CSM report impaired driving ability at presentation. Seventy-two percent of these patients reported improvements in their driving ability within 24 months of surgery. Surgical management of CSM can significantly improve patients’ driving abilities at 24 months and hence patients’ quality of life.
Family characteristics and childcare patterns associated with early social functioning in cancer‐bereaved parents
Snaman, Jennifer M. , Helton, Gabrielle, Feifer, Deborah , Baker, Justin N. , McCarthy, Sarah , Rosenberg, Abby R , Chen, Li , Mazzola, Emanuele , Broden, Elizabeth G. , Rosenberg, Abby R. , Wolfe, Joanne

Mayo Clinic

Cancer | April 15, 2024 | Volume: 130 | Issue: 16 | Pages: 2822-2833

10.1002/cncr.35325 | PMID 38620040 Get It

AbstractBackgroundBereaved parents experience life‐long grief after the death of their child from cancer. Parents who can integrate their grief and maintain their social functioning early in bereavement, even in the setting of concurrent psychosocial distress, have improved outcomes. Identifying the factors associated with bereaved parents' early social functioning can guide future supportive interventions.MethodsThe authors surveyed parents of children who died from cancer at two large centers 6–24 months after death, assessing bereavement experiences using validated and pilot tested tools. Univariable and multivariable logistical regression models were used to examine which family and child demographic, treatment, and end‐of‐life (EOL) factors were associated with maintained parental social functioning (T scores ≥40 on the Patient‐Reported Outcomes Measurement Information System Ability to Participate in Social Roles and Activities‐Short Form questionnaire).ResultsOne hundred twenty‐eight parents of 88 children participated (38% household response rate); most parents identified as female (63%) and White (88%). Parents' median age was 47 years (interquartile range, 10 years); and the median time from the child's death to survey completion was 13 months (interquartile range, 10 months). In multivariate modeling, parents without household material hardship and those who felt prepared for EOL circumstances had increased odds of maintained social functioning (odds ratio, 4.7 [95% confidence interval, 1.6–13.7; p < .004] and 5.5 [95% confidence interval, 1.9–15.9; p < .002], respectively).ConclusionsParents who felt prepared for their child's EOL and those without household material hardship were more likely to have maintained social functioning in the first 2 years after their child’s death. Interventions targeting EOL preparedness and alleviating household material hardship may improve bereavement outcomes.
Clinicopathologic Heterogeneity and Glial Activation Patterns in Alzheimer Disease
Frankenhauser, Isabelle , Peng, Zhongwei , Labuzan, Sydney A. , Boon, Baayla D.C. , Moloney, Christina M. , Pottier, Cyril , Wickland, Daniel P. , Tranovich, Jessica F., Wood, Ashley , Hinkle, Kelly M., Lincoln, Sarah, Spychalla, Anthony J., Przybelski, Scott A. , Kwan, Rain S., Lesser, Elizabeth R. , Carter, Rickey E. , Ross, Owen A. , Lachner, Christian , Ertekin‐Taner, Nilüfer , Ferman, Tanis J. , Fields, Julie A. , Nguyen, Aivi T. , Reichard, R. Ross , Graff‐Radford, Jonathan , Petersen, Ronald C. , Jack, Clifford R. , Kantarci, Kejal , Day, Gregory S. , Duara, Ranjan , Graff‐Radford, Neill R. , Lowe, Val J. , Murray, Melissa E. , Kouri, Naomi , Caetano-Anolles, Kelsey, Corriveau-Lecavalier, Nick , Wood, Ashley C., Lincoln, Sarah J, Engelberg-Cook, Erica , Crook, Julia E. , Jack, Clifford R , Ross, Owen A , Carter, Rickey E , Kantarci, Kejal , Day, Gregory S , Murray, Melissa E , Ferman, Tanis J , Nguyen, Aivi T , Pottier, Cyril , Caetano-Anollés, Kelsey , Corriveau‐Lecavalier, Nick , Wood, Ashley C., Senjem, Matthew L. , Schwarz, Christopher G. , Machulda, Mary M. , Ramanan, Vijay K. , Jones, David T. , Boeve, Bradley F. , Knopman, David S. , Duara, Ranjan , Dickson, Dennis W. , Vemuri, Prashanthi

Mayo Clinic

JAMA Neurology | April 15, 2024 | Volume: 81 | Issue: 6 | Pages: 619

10.1001/jamaneurol.2024.0784 | PMID 38619853 Get It

Importance Factors associated with clinical heterogeneity in Alzheimer disease (AD) lay along a continuum hypothesized to associate with tangle distribution and are relevant for understanding glial activation considerations in therapeutic advancement. Objectives To examine clinicopathologic and neuroimaging characteristics of disease heterogeneity in AD along a quantitative continuum using the corticolimbic index (CLix) to account for individuality of spatially distributed tangles found at autopsy. Design, Setting, and Participants This cross-sectional study was a retrospective medical record review performed on the Florida Autopsied Multiethnic (FLAME) cohort accessioned from 1991 to 2020. Data were analyzed from December 2022 to December 2023. Structural magnetic resonance imaging (MRI) and tau positron emission tomography (PET) were evaluated in an independent neuroimaging group. The FLAME cohort includes 2809 autopsied individuals; included in this study were neuropathologically diagnosed AD cases (FLAME-AD). A digital pathology subgroup of FLAME-AD cases was derived for glial activation analyses. Main Outcomes and Measures Clinicopathologic factors of heterogeneity that inform patient history and neuropathologic evaluation of AD; CLix score (lower, relative cortical predominance/hippocampal sparing vs higher, relative cortical sparing/limbic predominant cases); neuroimaging measures (ie, structural MRI and tau-PET). Results Of the 2809 autopsied individuals in the FLAME cohort, 1361 neuropathologically diagnosed AD cases were evaluated. A digital pathology subgroup included 60 FLAME-AD cases. The independent neuroimaging group included 93 cases. Among the 1361 FLAME-AD cases, 633 were male (47%; median [range] age at death, 81 [54-96] years) and 728 were female (53%; median [range] age at death, 81 [53-102] years). A younger symptomatic onset (Spearman ρ = 0.39, P &amp;lt; .001) and faster decline on the Mini-Mental State Examination (Spearman ρ = 0.27; P &amp;lt; .001) correlated with a lower CLix score in FLAME-AD series. Cases with a nonamnestic syndrome had lower CLix scores (median [IQR], 13 [9-18]) vs not (median [IQR], 21 [15-27]; P &amp;lt; .001). Hippocampal MRI volume (Spearman ρ = −0.45; P &amp;lt; .001) and flortaucipir tau-PET uptake in posterior cingulate and precuneus cortex (Spearman ρ = −0.74; P &amp;lt; .001) inversely correlated with CLix score. Although AD cases with a CLix score less than 10 had higher cortical tangle count, we found lower percentage of CD68-activated microglia/macrophage burden (median [IQR], 0.46% [0.32%-0.75%]) compared with cases with a CLix score of 10 to 30 (median [IQR], 0.75% [0.51%-0.98%]) and on par with a CLix score of 30 or greater (median [IQR], 0.40% [0.32%-0.57%]; P = .02). Conclusions and Relevance Findings show that AD heterogeneity exists along a continuum of corticolimbic tangle distribution. Reduced CD68 burden may signify an underappreciated association between tau accumulation and microglia/macrophages activation that should be considered in personalized therapy for immune dysregulation.
A Phase I Study of KIN-3248, an Irreversible Small-molecule Pan-FGFR Inhibitor, in Patients with Advanced FGFR2/3-driven Solid Tumors
Garmezy, Benjamin , Borad, Mitesh J. , Bahleda, Rastilav , Perez, Cesar A. , Chen, Li‐Tzong , Kato, Shumei , Oh, Do‐Youn , Severson, Paul , Tam, Betty Y. , Quah, Cheng S. , Harding, James J , Borad, Mitesh J , Chen, Li-Tzong , Garmezy, Benjamin , Harding, James J.

Mayo Clinic

Cancer Research Communications | April 11, 2024 | Volume: 4 | Issue: 4 | Pages: 1165-1173

10.1158/2767-9764.crc-24-0137 | PMID 38602417 Get It

Abstract Purpose: Despite efficacy of approved FGFR inhibitors, emergence of polyclonal secondary mutations in the FGFR kinase domain leads to acquired resistance. KIN-3248 is a selective, irreversible, orally bioavailable, small-molecule inhibitor of FGFR1-4 that blocks both primary oncogenic and secondary kinase domain resistance FGFR alterations. Experimental Design: A first-in-human, phase I study of KIN-3248 was conducted in patients with advanced solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822). The primary objective was determination of MTD/recommended phase II dose (RP2D). Secondary and exploratory objectives included antitumor activity, pharmacokinetics, pharmacodynamics, and molecular response by circulating tumor DNA (ctDNA) clearance. Results: Fifty-four patients received doses ranging from 5 to 50 mg orally daily across six cohorts. Intrahepatic cholangiocarcinoma (48.1%), gastric (9.3%), and urothelial (7.4%) were the most common tumors. Tumors harbored FGFR2 (68.5%) or FGFR3 (31.5%) alterations—23 (42.6%) received prior FGFR inhibitors. One dose-limiting toxicity (hypersensitivity) occurred in cohort 1 (5 mg). Treatment-related, adverse events included hyperphosphatemia, diarrhea, and stomatitis. The MTD/RP2D was not established. Exposure was dose proportional and concordant with hyperphosphatemia. Five partial responses were observed; 4 in FGFR inhibitor naïve and 1 in FGFR pretreated patients. Pretreatment ctDNA profiling confirmed FGFR2/3 alterations in 63.3% of cases and clearance at cycle 2 associated with radiographic response. Conclusion: The trial was terminated early for commercial considerations; therefore, RP2D was not established. Preliminary clinical data suggest that KIN-3248 is a safe, oral FGFR1-4 inhibitor with favorable pharmacokinetic parameters, though further dose escalation was required to nominate the MTD/RP2D. Significance: KIN-3248 was a rationally designed, next generation selective FGFR inhibitor, that was effective in interfering with both FGFR wild-type and mutant signaling. Clinical data indicate that KIN-3248 is safe with a signal of antitumor activity. Translational science support the mechanism of action in that serum phosphate was proportional with exposure, paired biopsies suggested phospho-ERK inhibition (a downstream target of FGFR2/3), and ctDNA clearance may act as a RECIST response surrogate.
Underlying Cerebral Small Vessel Disease May Predict Poor Neurologic Outcomes Following Traumatic Brain Injury (P2-14.017)
Salomon, Gary R., Hay, Sarah , Barrett, Kevin M. , Badi, Mohammed K.

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205677 Get It

Side-by-Side Comparison of Commonly Used Beat-to-Beat Blood Pressure Devices in the Autonomic Laboratory During the Valsalva Maneuver (S9.005)
Sletten, David M., Gehrking, Jade A., Conely, Damaris, McNamara, Sarah, Low, Phillip A. , McNamara, Sarah, Singer, Wolfgang

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205666 Get It

Long-term Outcomes in Seropositive Autoimmune Autonomic Ganglionopathy (S9.004)
Reiter-Campeau, Sandra , Sandroni, Paola , Benarroch, Eduardo E. , Cutsforth‐Gregory, Jeremy K. , Berini, Sarah E. , Low, Phillip A. , Shouman, Kamal , Mauermann, Michelle L. , Dubey, Divyanshu , McKeon, Andrew , Coon, Elizabeth A. , Singer, Wolfgang

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000205398 Get It

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer
Yaeger, Rona , Uboha, Nataliya V. , Pelster, Meredith S. , Bekaii‐Saab, Tanios , Barve, Minal , Saltzman, Joel , Sabari, Joshua K. , Peguero, Julio A. , Paulson, Andrew Scott , Jänne, Pasi A. , Anderes, Kenna , Velastegui, Karen , Yan, Xiaohong , Der‐Torossian, Hirak , Bekaii-Saab, Tanios S , Cruz-Correa, Marcia , Anderes, Kenna , Velastegui, Karen , Yan, Xiaohong , Der-Torossian, Hirak , Klempner, Samuel J , Kopetz, Scott , Cruz‐Correa, Marcia , Klempner, Samuel J. , Kopetz, Scott

Mayo Clinic

Cancer Discovery | April 8, 2024 | Volume: 14 | Issue: 6 | Pages: 982-993

10.1158/2159-8290.cd-24-0217 | PMID 38587856 Get It

Abstract Adagrasib, an irreversible, selective KRASG12C inhibitor, may be an effective treatment in KRASG12C-mutated colorectal cancer, particularly when combined with an anti-EGFR antibody. In this analysis of the KRYSTAL-1 trial, patients with previously treated KRASG12C-mutated unresectable or metastatic colorectal cancer received adagrasib (600 mg twice daily) plus cetuximab. The primary endpoint was objective response rate (ORR) by blinded independent central review. Ninety-four patients received adagrasib plus cetuximab. With a median follow-up of 11.9 months, ORR was 34.0%, disease control rate was 85.1%, and median duration of response was 5.8 months (95% confidence interval [CI], 4.2–7.6). Median progression-free survival was 6.9 months (95% CI, 5.7–7.4) and median overall survival was 15.9 months (95% CI, 11.8–18.8). Treatment-related adverse events (TRAEs) occurred in all patients; grade 3–4 in 27.7% and no grade 5. No TRAEs led to adagrasib discontinuation. Exploratory analyses suggest circulating tumor DNA may identify features of response and acquired resistance. Significance: Adagrasib plus cetuximab demonstrates promising clinical activity and tolerable safety in heavily pretreated patients with unresectable or metastatic KRASG12C-mutated colorectal cancer. These data support a potential new standard of care and highlight the significance of testing and identification of KRASG12C mutations in patients with colorectal cancer. This article is featured in Selected Articles from This Issue, p. 897 See co-corresponding author Rona Yaeger discuss this research article, published simultaneously at the AACR Annual Meeting 2024: https://vimeo.com/932606282/f27a6e46f4